Nektar Therapeutics Soars 12.94% on Jefferies Upgrade
Mover TrackerMonday, Apr 14, 2025 7:06 am ET
1min readNektar Therapeutics' stock surged by 12.94% in pre-market trading on April 14, 2025, marking a significant rise in investor confidence.
Nektar Therapeutics (NKTR) recently experienced a notable stock surge following an upgrade to a "Buy" rating by Jefferies. The investment firm highlighted the company's potential for growth and innovation, which likely contributed to the positive market sentiment.
Verition Fund Management LLC has increased its stake in
, acquiring an additional 100,454 shares in the last quarter. This move by a prominent investment firm suggests a strong belief in the company's future prospects and may have influenced the recent stock price increase.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet